EndoRun 2024: Stakeholders join forces to amplify endometriosis awareness

With 42 million women in India suffer from endometriosis, diagnosis of the condition is often delayed by 6-10 years, significantly reducing overall quality of life

New Delhi: Patient Academy for Innovation and Research (PAIR) with support from Bayer kicked off the final edition of the EndoRun in Mumbai at MGM Institute of Health Sciences (MGMIHS), Navi Mumbai.
The EndoRun is a mass awareness initiative that brings together patients and their families, healthcare providers, researchers, and advocates to spotlight the cause of endometriosis. The goal is to raise awareness about endometriosis, spark a national conversation around the condition, and call for greater support and resources for individuals and families affected by it.
Endometriosis is a common, chronic, gynaecological condition, which affects over 247 million women globally and 42 million women in India. It is a condition in which tissue like the lining of the uterus grows outside of the uterus. Women with endometriosis suffer from chronic pelvic pain, heavy menstrual bleeding, fatigue, depression, and infertility. Diagnosis of the condition is often delayed by 6-10 years, significantly reducing a woman’s overall quality of life.
Dr. Imran Hamzawala, Gynaecologist, Gynaec- Cancer Specialist, Robotic & Laparoscopic Surgeon along with other dignitaries were present at the event and spoke about the current challenges faced by women who suffer from endometriosis, the importance of early detection, and the need for clinical advancements in this area.
“Painful periods have been normalized in society, and so women often go through their periods as just one of those things they must endure in life. Therefore, it is important to help women distinguish discomfort from pain. The Bayer For Her initiative attempts to bring this conversation of care through a self-assessment form which helps women evaluate discreetly if they are suffering from endometriosis. From there women can then determine whether they need to seek a doctor’s guidance and check for the best available treatment options for them.  Early diagnosis and treatment can prevent long-term suffering and minimize the necessity for surgical interventions”, said Shweta Rai, Managing Director, Bayer Zydus Pharma and Country Division Head, Bayer Pharmaceuticals, South Asia
Dr. Ratna Devi, Director, Patient Academy for Innovation and Research, said, “It is crucial to address the issue of delayed diagnosis and treatment among women enduring severe symptoms and debilitating pain. Unfortunately, their concerns often go unrecognized or dismissed, reflecting a broader societal neglect of women’s health. Advocating for improved early detection and treatment options is essential. Establishing a supportive and inclusive environment where women feel empowered to share their experiences and offer mutual support emerges as a pressing need.”
Previous editions of the initiative were conducted in Delhi, Hyderabad, and Lucknow, with the final leg taking place in Mumbai on 8th April.